The Relative Strength (RS) Rating for Alkermes (ALKS) moved up into a new percentile Monday, as it got a lift from 64 to 76.
↑ XIBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the best stocks often have an 80 or better RS Rating as they launch their largest price moves. See if Alkermes can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Alkermes is trying to complete a cup without handle with a 32.88 buy point. See if the stock can break out in volume at least 40% above average.
The company reported negative growth for both the top and bottom lines last quarter. Alkermes is expected to release its next quarterly numbers on or around Oct. 23.
The company holds the No. 19 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics (ADMA), Catalyst Pharmaceuticals (CPRX) and United Therapeutics (UTHR) are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。